RE: "I too wonder why they keep beating the price up"
GHDX share price held up very well during the bear market in 2008 but has lagged badly during the rebound. This is mostly likely because during bad markets, quality, predictable stock hold up better....during rebounds, the market favors riskier, lower quality names. I have made a small killing the last several months aggressively trading small, speculative biotechs....you could almost throw a dart....but I've been holding GHDX for 5 years.
At some point in the future, quality stock in this space will rotate back into favor and GHDX will participate.
i will say this though....the market did want to see a wider approval for the colon test....will still may happen...but product line expansion will be vital to any sustainable growth.....imo.....will post S&P's comments on GHI when they are released....
05/06/10 10:30 am ET ... S&P REITERATES BUY OPINION ON SHARES OF GENOMIC HEALTH (GHDX 15.9****): Q1 net loss of $0.07, vs. loss of $0.16, is $0.03 wider than our loss view. Oncotype DX revenues rose 22%, but were $2M below our estimate, but GHDX reaffirmed '10 revenue and net income targets.We maintain a positive long-term outlook for Oncotype DX, but see near-term results dampended by macroeconomic headwinds.We view favorably GHDX's positive cash flows, despite sales force and global infrastructure expansion.We lower our '10 EPS est by $0.02 to $0.05 and '11's by $0.17 to $0.55. On more modest Oncotype DX expansion, and trim our P/E-based target price by $1 to $22.